UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/067,996	02/08/2002	Ruiping Liu	MEMORY-2	9946	
24980 7590 05/24/2007 MILLEN, WHITE, ZELANO & BRANIGAN, PC		EXAMINER			
2200 CLARENDON BLVD			BERCH, I	BERCH, MARK L	
SUITE 1400 ARLINGTON,	VA 22201		ART UNIT	PAPER NUMBER	
,	,		1624		
			MAIL DATE	DELIVERY MODE	
			05/24/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
		10/067,996	LIU ET AL.			
	Office Action Summary	Examiner	Art Unit			
		/Mark L. Berch/	1624			
Period fo	The MAILING DATE of this communication a or Reply	ppears on the cover sheet with the o	correspondence address			
THE - Exte after - If the - If NO - Failt Any	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION insions of time may be available under the provisions of 37 CFR of SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a representation of the provision of the provis	1.  1.136(a). In no event, however, may a reply be tireply within the statutory minimum of thirty (30) day of will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE.	nely filed  rs will be considered timely. I the mailing date of this communication. D (35 U.S.C. § 133)			
Status						
1)🖂	Responsive to communication(s) filed on 23	April 2007.				
		nis action is noń-final.				
3)	~					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
5)□ 6)⊠ 7)□	4) ⊠ Claim(s) <u>1,4-15,30-32,60,61,72,100-102 and 119</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) □ Claim(s) is/are allowed.  6) ⊠ Claim(s) <u>1,4-15,30-32,60,61,72,100-102 and 119</u> is/are rejected.					
Applicat	ion Papers		•			
9) The specification is objected to by the Examiner.						
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)	The oath or declaration is objected to by the I	Examiner. Note the attached Office	Action or form PTO-152.			
Priority ι	under 35 U.S.C. § 119					
a)	Acknowledgment is made of a claim for foreig  All b) Some * c) None of:  1. Certified copies of the priority document  2. Certified copies of the priority document  3. Copies of the certified copies of the priority document  application from the International Bure  See the attached detailed Office action for a list	nts have been received.  nts have been received in Applicati  iority documents have been receive  au (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachmen	t(s)					
	e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/06 r No(s)/Mail Date	8) 5) Notice of Informal P 6) Other:	atent Application (PTO-152)			

Application/Control Number: 10/067,996

Art Unit: 1624

## DETAILED ACTION

The removal of R1 = alkyl overcomes the rejection over JP 2000-072773, Kelley(1990); the elimination of R1 as H or alkyl eliminates Bourguignon.

Applicants' arguments concerning compound 80 of Kelley(1997) are deemed persuasive.

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 4-15, 30-32, 60-61, 72, 100-102, 119 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The amendments to claims 4-5 have rendered unclear what applicants actually intend for claim 1. Claim 1 has cycloalkyl and cycloalkyl-alkyl, without any provision for substitution. But applicants have not amended claims 4-5, to specifically provide for substituted versions of these two, which implies that applicants do indeed intend for claim 1 to cover at least some sort of substitution for cycloalkyl or cycloalkyl-alkyl. If that was not the intent, then these claims 4-5 are improperly dependent on claim on claim 1.

## Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29

Application/Control Number: 10/067,996

Art Unit: 1624

USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 3-36, 60-61, 71-74, 77, 80, 94-119 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 22-53, 62-67, 72-118 of copending Application No. 10845354. Although the conflicting claims are not identical, they are not patentably distinct from each other because of a lack of patentable distinction.

There is ordinarily no patentable distinction between compositions of matter and methods. Hence, in the absence of a Terminal Disclaimer, an obviousness-type Double Patenting rejection may be made. See *In re Boylan*, 157 USPQ 370 [The patent had a composition of matter and a method of making it; the application had the method of use]; *Ex parte MacAdams*, 206 USPQ 445 [The patent had a composition of matter; the application had the method of use]; *Geneva Pharmaceuticals Inc. v. GlaxoSmithKline PLC*, 68 USPQ2d 1865 (CA FC 2003) [The earlier patent was drawn to method of use, the later

Application/Control Number: 10/067,996

Art Unit: 1624

three patents, held invalid in "Geneva II" were drawn to somewhat narrower versions of the composition of matter]; *Mosler Safe & Lock Co. v. Mosler, Bahmann & Co.*, 127 U.S. 354, 218 S.Ct. 1148 (1888) [the first patent was of an article; the second patent, held invalid, was for a method of making it].

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

The traverse is unpersuasive. The support for the proposition occurs in the cases cited above. The fact that restriction may or may ot have been made in oteh cases is not the point here; what matters here is only that no restriction was made in the parent here.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to /Mark L. Berch/ whose telephone number is 571-272-0663. The examiner can normally be reached on M-F 7:15 - 3:45.

Art Unit: 1624

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on (571)272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Mark L. Berch/ Primary Examiner Art Unit 1624

5/21/07